It is perhaps safe to state that there are, to the best of our knowledge, no successful advanced phase II or III trials on any brain disorder centered on KCC2 -targeting molecules, in spite of the immense investments by the pharmaceutical industry. Here, SLC12A5 is linked to brain disorder.